EGFR and non-small cell lung carcinoma: The first-line study EXCLAIM-2 (NCT04129502) of mobocertinib for treating locally advanced or metastatic EGFR ex20ins mutant NSCLC was terminated due to lack of efficacy (failure to improve PFS significantly) (72).